Complete the form below to unlock access to ALL audio articles.
The first international consensus has been published on how to diagnose and treat a rare condition, sometimes known as ‘dancing eyes and feet syndrome’.
Experts from Evelina London Children’s Hospital developed the guidance in collaboration with a worldwide panel of experts and families of children with the condition. The mother of a boy who has the syndrome said the care she received has helped to get her little boy back.
Opsoclonus-myoclonus syndrome is a very rare disease, estimated to affect around one in every 3-5 million children. It is sometimes known as ‘dancing eye syndrome’, as it causes rapid and involuntary eye movements. Patients can also be unsteady or lose their ability to stand and walk. It can cause significant distress and inability to sleep.
The condition usually affects children, and is often caused by a tumour, usually in the chest or abdomen, which causes the immune system to attack nerves around the body.
Rafferty Whitbread-Ward, from Deal in Kent, was diagnosed with opsoclonus-myoclonus syndrome at Evelina London in autumn 2021. His mum, Samantha Whitbread, 32, said she first noticed a change at around eight months old: “When Rafferty was first born he was a very happy boy and was meeting all of his milestones. But within the same month that he started crawling, we noticed the development dropping off.
“After a while he started to have tremors in his arms and legs and his eyes started shaking and rolling back in his head. He was referred to a specialist, but in the week of his first birthday, he was really shaky and distressed, so we had an emergency appointment at the hospital.”
After initial tests, Rafferty was referred to Evelina London Children’s Hospital where he was diagnosed as having opsoclonus-myoclonus syndrome and a tumour in his adrenal gland.
Samantha said: “It’s such a rare disease, it took a while to get the diagnosis, but as soon as they worked out what it was, it was amazing. We got straight onto a cancer treatment pathway at the Royal Marsden Hospital, he had surgery, steroid treatment and physical therapy. He’s improved so much and bit by bit we’ve got our little boy back.”
Evelina London Children’s Hospital is a centre of excellence in caring for children with opsoclonus-myoclonus syndrome, co-managing the condition with the Royal Marsden Hospital in the 50% of children with this rare neurological syndrome who have tumours.
Dr Ming Lim, who led the development of the consensus, said: “Because opsoclonus-myoclonus syndrome is so rare, many clinical staff won’t have come across the condition in their careers, and it can be difficult to identify, and very difficult to research.”
“We hope that by creating this guidance, we can improve support for families and their clinicians. Families have told us that they have felt ‘seen and heard’ after reading it, so for those who have experienced the condition, it’s been emotional to see their experience reflected back. For children who are diagnosed in the future, it’s an important step that we are sharing knowledge globally and building consensus on the best approach.”
Rafferty, now 18 months old, is making good progress. His mum Samantha said it has been a difficult time, but that support from their family and the medical team has helped: “The staff at Evelina London were incredible. Because Rafferty was so young we couldn’t explain to him what was going on. Everyone we met took the time to explain what was happening and kept us as involved as possible. That helped to keep us calm, so that we could keep Rafferty calm.”
Reference: Rossor T, Yeh EA, Khakoo Y, et al. Diagnosis and Management of Opsoclonus-Myoclonus-Ataxia Syndrome in Children: An International Perspective. Neurology - Neuroimmunology Neuroinflammation. 2022;9(3). doi:10.1212/NXI.0000000000001153
This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.
